Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 27

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 27
---
, Series
J Warrants, and Series K Warrants issued in prior transactions, pursuant to which the holders agreed to exercise certain of such warrants
in exchange for a reduction in exercise price of each warrant to $3.10 per share. An aggregate of 20,041 warrants were exercised for aggregate
gross proceeds of approximately $62,000, before estimate offering expenses.

Since their respective dates
of issuance, we have issued 1,529,030,000 Ordinary Shares upon exercises of the Series H Warrants, Series J Warrants and Series K Warrants,
including warrants exercised pursuant to the terms of the 2025 Warrant Agreements (other than shares held in abeyance).

On June 11, 2025, we held
the June 2025 GM and our shareholders passed resolutions to, among other things, subdivide our Ordinary Shares of £0.00005 nominal
value each into one Ordinary Share of £0.000001 nominal value and 49 D deferred shares of £0.000001 nominal value each.

On July 31, 2025, we effected
a ratio change in the number of Ordinary Shares represented by our Depositary Shares from 10,000 Ordinary Shares per Depositary Share
to 100,000 Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued.

Options

We have established the Biodexa
Pharmaceuticals PLC Enterprise Management Incentive and Unapproved Option Scheme to allow us to grant options to purchase Ordinary Shares (in the form of Depositary Shares) to employees and directors of the Company or any of its subsidiaries for the purpose of attracting, rewarding and retaining such persons. The Plan was originally adopted in December 2014 and amended on April 11, 2024 to govern the grant of tax-advantaged enterprise management incentive stock options and unapproved stock options by the Company. As of June 30, 2025, there were options to purchase 313,070,788Ordinary Shares. The options lapse after ten years from the date of
the grant. As of June 30, 2025, the weighted average remaining life of the options was 8.7 years.

| 16 |

In connection with our acquisition
of DARA Biosciences, Inc., or DARA, in December 2015, we assumed all of DARA’s outstanding options, or DARA Options. As of June
30, 2025 there were outstanding DARA Options to purchase six Ordinary